HASBROUCK HEIGHTS, NJ--(BUSINESS WIRE)--Aug. 29, 2006--Nymox Pharmaceutical Corporation’s (NASDAQ: NYMX) AlzheimAlert(TM) and NicAlert(TM) products have recently been profiled in new media reports. AlzheimAlert(TM), the Company’s innovative aid to the diagnosis of Alzheimer’s disease, was featured in the August 28 edition of The Herald, Scotland’s leading national quality newspaper, and in The Herald Online, the online version of the paper. CNS Drug News, a leading industry publication published in the U.K., reported in August on the use of NicAlert(TM) in a large smoking cessation trial in the U.K. The same issue (No. 143) of CNS Drug News also reported on a new study that found evidence that the use of statin drugs significantly protected against cognitive decline and on Nymox’s patent position on the use of statins for the prevention and treatment of Alzheimer’s disease.
